Clinical Trial Update: Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating rituximab in addition to standard care for newly presenting thrombotic thrombocytopenic purpura has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Thrombotic Thrombocytopenic Purpura | Phase 1, Phase 2 | Status: WITHDRAWN